Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-04-2504PMID 15897567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)

  2006cited by this paper
• Vascular targeting therapies for treatment of malignant disease

  2005cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.

  2004cited by this paper
• Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

  2004cited by this paper
• Vascular Targeting Agents as Cancer Therapeutics

  2004cited by this paper
• Angiogenesis in health and disease

  2003cited by this paper
• Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

  2003cited by this paper
• 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

  2003cited by this paper
• Visualizing metabolic changes in breast‐cancer tissue using 1H‐NMR spectroscopy and self‐organizing maps

  2003cited by this paper
• 1H MR spectroscopy of brain tumours and masses

  2003cited by this paper
• Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.

  2003cited by this paper
• Antivascular therapy of cancer: DMXAA.

  2003cited by this paper
• Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

  2002cited by this paper
• Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.

  2002cited by this paper
• 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy

  2002cited by this paper
• Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma.

  2002cited by this paper
• Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice

  2001cited by this paper
• Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

  2001cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Tumour phospholipid metabolism

  1999cited by this paper
• Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.

  1999cited by this paper
• Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit

  1999cited by this paper
• Tumour vasculature as a target for cancer therapy.

  1999cited by this paper
• United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

  1998cited by this paper
• In vivo 31p mrs: absolute concentrations, signal‐to‐noise and prior knowledge

  1995cited by this paper
• Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

  1993cited by this paper
• Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.

  1993cited by this paper
• Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.

  1991cited by this paper
• Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation.

  1989cited by this paper
• Flavone acetic acid--preclinical and clinical activity.

  1989cited by this paper
• Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge

  1988cited by this paper
• Toxic effect of tumor necrosis factor on tumor vasculature in mice.

  1988cited by this paper
• Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy

  1986cited by this paper
• How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

  1986cited by this paper
• Image selected in-vivo spectroscopy (ISIS)

  1985cited by this paper
• Endothelial-cell proliferation in experimental tumours.

  1982cited by this paper
• Induction of apoptosis in proliferating human

  year unknowncited by this paper

• Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors

  2021influential citation
• Magnetic Resonance Imaging for Translational Research in Oncology

  2019cites this paper
• An overview on Vadimezan (DMXAA): The vascular disrupting agent

  2018cites this paper
• Non‐invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism

  2016cites this paper
• Novel Synergistic Therapy for Metastatic Breast Cancer: Magnetic Nanoparticle Hyperthermia of the Neovasculature Enhanced by a Vascular Disruption Agent

  2012cites this paper
• The Cellular and Molecular Actions of DMXAA (5, 6-dimethylxanthenone-4-acetic acid) on HUVE-12 Endothelial Cells

  2012cites this paper
• Magnetic Resonance Spectroscopy of Cancer Metabolism and Response to Therapy

  2012cites this paper
• Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents

  2011cites this paper
• Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.

  2011cites this paper
• Metabolomic Studies on Cancer and on Anticancer Drugs by NMR Ex Vivo

  2011cites this paper
• The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs)

  2010cites this paper
• Lessons from Animal Imaging in Preclinical Models

  2010cites this paper
• In vivo small animal imaging: current status and future prospects.

  2010cites this paper
• Magnetic resonance spectroscopy of living tissues.

  2009cites this paper
• Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives

  2009cites this paper
• Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.

  2008cites this paper
• Monitoring response to chemotherapy of non‐Hodgkin's lymphoma xenografts by T2‐weighted and diffusion‐weighted MRI

  2008cites this paper
• The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

  2008cites this paper
• Effect of Gd‐DTPA‐BMA on choline signals of HT29 tumors detected by in vivo 1H MRS

  2008influential citation
• Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

  2008cites this paper
• In vivo Monitoring Response to Chemotherapy of Human Diffusion Large B-Cell Lymphoma Xenografts in SCID Mice by 1 H and 31 P

  2007cites this paper
• In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.

  2007cites this paper
• Using metabolomics to monitor anticancer drugs.

  2007cites this paper
• Highlights from: The 2007 Prostate Cancer Symposium, February 22-24, 2007; Orlando, FL.

  2007cites this paper
• Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.

  2007cites this paper
• 2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006

  2007cites this paper
• N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice

  2007cites this paper
• CENU treatment induced bystander effects which are effective on parental and non-parental tumors and have a phospholipid metabolism proton NMR spectroscopy signature.

  2006cites this paper
• Current Awareness in NMR in Biomedicine

  2006cites this paper
• The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS

  2006cites this paper
• Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

  2006cites this paper
• Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

  2006cites this paper
• 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)

  2006cites this paper
• The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.

  2006cites this paper